| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pancreatic Neoplasms | 75 | 2022 | 5251 | 4.610 |
Why?
|
| Tomography, X-Ray Computed | 74 | 2022 | 7779 | 4.380 |
Why?
|
| Carcinoma, Pancreatic Ductal | 28 | 2022 | 1826 | 2.300 |
Why?
|
| Radiology | 11 | 2023 | 426 | 2.050 |
Why?
|
| Radiography, Abdominal | 10 | 2020 | 128 | 1.850 |
Why?
|
| Radiography, Dual-Energy Scanned Projection | 6 | 2020 | 57 | 1.800 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 11 | 2020 | 382 | 1.700 |
Why?
|
| Pancreas | 14 | 2018 | 744 | 1.410 |
Why?
|
| Adenocarcinoma | 21 | 2020 | 7909 | 1.220 |
Why?
|
| Neuroendocrine Tumors | 6 | 2024 | 652 | 1.200 |
Why?
|
| Abdomen | 3 | 2020 | 349 | 1.160 |
Why?
|
| Image Processing, Computer-Assisted | 13 | 2019 | 1688 | 1.130 |
Why?
|
| Workflow | 3 | 2017 | 277 | 0.970 |
Why?
|
| Diagnostic Imaging | 16 | 2017 | 1174 | 0.960 |
Why?
|
| Quality Assurance, Health Care | 3 | 2016 | 595 | 0.940 |
Why?
|
| Pancreatic Cyst | 6 | 2015 | 111 | 0.880 |
Why?
|
| Pancreaticoduodenectomy | 12 | 2020 | 706 | 0.850 |
Why?
|
| Radiology Information Systems | 8 | 2002 | 119 | 0.830 |
Why?
|
| Peer Review, Research | 1 | 2023 | 66 | 0.820 |
Why?
|
| Multidetector Computed Tomography | 4 | 2017 | 147 | 0.780 |
Why?
|
| Magnetic Resonance Imaging | 25 | 2021 | 7890 | 0.780 |
Why?
|
| Editorial Policies | 1 | 2021 | 78 | 0.700 |
Why?
|
| Neoplasm Staging | 26 | 2021 | 14003 | 0.680 |
Why?
|
| Documentation | 2 | 2018 | 213 | 0.630 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2020 | 167 | 0.630 |
Why?
|
| Pancreatectomy | 6 | 2018 | 696 | 0.590 |
Why?
|
| Pancreatic Ducts | 4 | 2018 | 127 | 0.580 |
Why?
|
| Humans | 128 | 2024 | 270462 | 0.550 |
Why?
|
| Periodicals as Topic | 1 | 2021 | 317 | 0.550 |
Why?
|
| Gastrinoma | 3 | 2014 | 25 | 0.540 |
Why?
|
| Neoadjuvant Therapy | 9 | 2022 | 5225 | 0.540 |
Why?
|
| Insulinoma | 3 | 2014 | 53 | 0.530 |
Why?
|
| Societies, Medical | 3 | 2021 | 1319 | 0.520 |
Why?
|
| Radiology Department, Hospital | 1 | 2016 | 53 | 0.500 |
Why?
|
| Reproducibility of Results | 13 | 2020 | 6190 | 0.480 |
Why?
|
| Endosonography | 9 | 2014 | 551 | 0.470 |
Why?
|
| Radiographic Image Enhancement | 8 | 2019 | 410 | 0.470 |
Why?
|
| Carcinoma, Acinar Cell | 2 | 2013 | 87 | 0.460 |
Why?
|
| Contrast Media | 14 | 2020 | 1498 | 0.450 |
Why?
|
| Computer Systems | 5 | 2001 | 113 | 0.440 |
Why?
|
| Liver Neoplasms | 7 | 2020 | 4815 | 0.440 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2018 | 1300 | 0.410 |
Why?
|
| Models, Organizational | 1 | 2012 | 69 | 0.400 |
Why?
|
| Diagnosis, Differential | 16 | 2020 | 4829 | 0.390 |
Why?
|
| Body Burden | 1 | 2011 | 64 | 0.390 |
Why?
|
| Signal-To-Noise Ratio | 4 | 2019 | 127 | 0.370 |
Why?
|
| Sensitivity and Specificity | 11 | 2020 | 5171 | 0.360 |
Why?
|
| Safety Management | 1 | 2011 | 135 | 0.360 |
Why?
|
| Imaging, Three-Dimensional | 2 | 2009 | 908 | 0.360 |
Why?
|
| Radiation Protection | 1 | 2011 | 204 | 0.350 |
Why?
|
| Neoplasms, Second Primary | 2 | 2015 | 1387 | 0.340 |
Why?
|
| Digestive System Neoplasms | 2 | 2020 | 78 | 0.330 |
Why?
|
| History, 21st Century | 2 | 2021 | 418 | 0.330 |
Why?
|
| Peritoneal Neoplasms | 2 | 2015 | 855 | 0.320 |
Why?
|
| Retrospective Studies | 26 | 2022 | 39760 | 0.320 |
Why?
|
| Biliary Tract Diseases | 1 | 2009 | 65 | 0.320 |
Why?
|
| Quality Improvement | 1 | 2016 | 912 | 0.310 |
Why?
|
| Aged, 80 and over | 26 | 2020 | 30976 | 0.310 |
Why?
|
| Carcinoma, Papillary | 3 | 2018 | 566 | 0.310 |
Why?
|
| Middle Aged | 51 | 2022 | 90192 | 0.310 |
Why?
|
| Brain Neoplasms | 2 | 2021 | 4955 | 0.310 |
Why?
|
| Iodine | 2 | 2019 | 55 | 0.310 |
Why?
|
| Male | 55 | 2022 | 128209 | 0.290 |
Why?
|
| Deoxycytidine | 8 | 2022 | 1389 | 0.290 |
Why?
|
| Aged | 42 | 2020 | 73248 | 0.270 |
Why?
|
| Pelvic Neoplasms | 2 | 2005 | 199 | 0.270 |
Why?
|
| Adult | 41 | 2022 | 81851 | 0.270 |
Why?
|
| Algorithms | 9 | 2019 | 3900 | 0.260 |
Why?
|
| Internet | 5 | 2000 | 690 | 0.260 |
Why?
|
| Neoplasm Recurrence, Local | 5 | 2022 | 10382 | 0.260 |
Why?
|
| Positron-Emission Tomography | 4 | 2021 | 2196 | 0.260 |
Why?
|
| Female | 56 | 2022 | 148723 | 0.250 |
Why?
|
| Carcinoma, Neuroendocrine | 2 | 2013 | 743 | 0.250 |
Why?
|
| Observer Variation | 3 | 2016 | 709 | 0.250 |
Why?
|
| Delivery of Health Care | 1 | 2012 | 854 | 0.250 |
Why?
|
| Carcinoid Tumor | 1 | 2007 | 280 | 0.250 |
Why?
|
| Paraganglioma | 1 | 2007 | 200 | 0.240 |
Why?
|
| Clinical Protocols | 2 | 2017 | 478 | 0.240 |
Why?
|
| Phantoms, Imaging | 4 | 2019 | 1330 | 0.240 |
Why?
|
| Evaluation Studies as Topic | 3 | 2017 | 452 | 0.220 |
Why?
|
| Urinary Calculi | 1 | 2003 | 29 | 0.220 |
Why?
|
| Flank Pain | 1 | 2003 | 10 | 0.220 |
Why?
|
| Publishing | 2 | 2023 | 193 | 0.220 |
Why?
|
| Kidney Diseases | 2 | 2006 | 693 | 0.210 |
Why?
|
| Lymphatic Metastasis | 4 | 2021 | 4957 | 0.210 |
Why?
|
| Triiodobenzoic Acids | 3 | 2015 | 69 | 0.210 |
Why?
|
| London | 1 | 2021 | 14 | 0.200 |
Why?
|
| Antineoplastic Protocols | 1 | 2022 | 36 | 0.200 |
Why?
|
| Radiography | 3 | 2023 | 1986 | 0.190 |
Why?
|
| User-Computer Interface | 2 | 2000 | 267 | 0.190 |
Why?
|
| Cadaver | 1 | 2021 | 202 | 0.190 |
Why?
|
| Preoperative Care | 3 | 2016 | 1552 | 0.180 |
Why?
|
| Splenic Rupture | 1 | 2000 | 6 | 0.180 |
Why?
|
| Radiologists | 1 | 2023 | 178 | 0.180 |
Why?
|
| Mental Recall | 1 | 2021 | 171 | 0.180 |
Why?
|
| Splenic Artery | 1 | 2000 | 54 | 0.180 |
Why?
|
| Aneurysm, Ruptured | 1 | 2000 | 44 | 0.180 |
Why?
|
| Hospital Information Systems | 1 | 2000 | 47 | 0.170 |
Why?
|
| Antimetabolites, Antineoplastic | 4 | 2014 | 1347 | 0.170 |
Why?
|
| Neoplasm Metastasis | 6 | 2018 | 5309 | 0.170 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 8 | 2022 | 16640 | 0.170 |
Why?
|
| Pancreatitis, Chronic | 1 | 2020 | 130 | 0.160 |
Why?
|
| Practice Guidelines as Topic | 4 | 2020 | 2392 | 0.160 |
Why?
|
| Biopsy, Fine-Needle | 3 | 2011 | 687 | 0.160 |
Why?
|
| Adenocarcinoma, Mucinous | 2 | 2016 | 441 | 0.160 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2022 | 686 | 0.160 |
Why?
|
| Gastrointestinal Diseases | 2 | 2022 | 607 | 0.160 |
Why?
|
| Kidney Neoplasms | 4 | 2013 | 3107 | 0.160 |
Why?
|
| History, 20th Century | 1 | 2021 | 543 | 0.150 |
Why?
|
| Software | 5 | 2017 | 1356 | 0.150 |
Why?
|
| Noise | 1 | 2017 | 33 | 0.140 |
Why?
|
| Education, Distance | 1 | 1999 | 100 | 0.140 |
Why?
|
| Neoplasms, Cystic, Mucinous, and Serous | 1 | 2018 | 107 | 0.140 |
Why?
|
| Pancreaticojejunostomy | 2 | 2013 | 14 | 0.140 |
Why?
|
| Thoracic Neoplasms | 1 | 2020 | 352 | 0.140 |
Why?
|
| Ligaments | 2 | 2009 | 42 | 0.140 |
Why?
|
| Photons | 1 | 2020 | 536 | 0.140 |
Why?
|
| Gastric Emptying | 2 | 2013 | 99 | 0.140 |
Why?
|
| Patient Selection | 5 | 2018 | 2026 | 0.140 |
Why?
|
| Prognosis | 11 | 2020 | 22466 | 0.130 |
Why?
|
| Gadolinium DTPA | 1 | 2016 | 173 | 0.130 |
Why?
|
| Genital Neoplasms, Female | 3 | 2017 | 788 | 0.130 |
Why?
|
| Pancreatic Diseases | 2 | 2009 | 113 | 0.130 |
Why?
|
| Abdomen, Acute | 1 | 1996 | 38 | 0.130 |
Why?
|
| Efficiency, Organizational | 1 | 2016 | 89 | 0.130 |
Why?
|
| Follow-Up Studies | 11 | 2018 | 15188 | 0.130 |
Why?
|
| Gaucher Disease | 1 | 1995 | 17 | 0.130 |
Why?
|
| Radiation Dosage | 2 | 2020 | 1042 | 0.130 |
Why?
|
| Intestinal Neoplasms | 2 | 2003 | 203 | 0.120 |
Why?
|
| Cholangiopancreatography, Magnetic Resonance | 1 | 2015 | 24 | 0.120 |
Why?
|
| Hematopoiesis, Extramedullary | 1 | 1995 | 43 | 0.120 |
Why?
|
| Hemangioma, Cavernous | 1 | 1995 | 32 | 0.120 |
Why?
|
| Patient Education as Topic | 1 | 2000 | 744 | 0.120 |
Why?
|
| Databases as Topic | 2 | 2008 | 136 | 0.120 |
Why?
|
| Peritoneum | 1 | 2015 | 150 | 0.120 |
Why?
|
| Abdominal Neoplasms | 1 | 2017 | 250 | 0.120 |
Why?
|
| Image Interpretation, Computer-Assisted | 2 | 2016 | 585 | 0.120 |
Why?
|
| Population Surveillance | 1 | 2018 | 645 | 0.120 |
Why?
|
| Mammography | 1 | 2000 | 1052 | 0.110 |
Why?
|
| Adenoma, Oxyphilic | 1 | 1994 | 76 | 0.110 |
Why?
|
| Choledochostomy | 1 | 2013 | 10 | 0.110 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2022 | 2647 | 0.110 |
Why?
|
| ROC Curve | 2 | 2007 | 1249 | 0.110 |
Why?
|
| Pancreatitis | 2 | 2008 | 294 | 0.110 |
Why?
|
| Tomography, Spiral Computed | 2 | 2004 | 128 | 0.110 |
Why?
|
| Combined Modality Therapy | 8 | 2019 | 9039 | 0.110 |
Why?
|
| Anastomotic Leak | 1 | 2013 | 83 | 0.100 |
Why?
|
| Liver | 3 | 2006 | 3086 | 0.100 |
Why?
|
| Stomach | 1 | 1995 | 402 | 0.100 |
Why?
|
| Fluoroscopy | 1 | 2013 | 223 | 0.100 |
Why?
|
| Postoperative Complications | 3 | 2018 | 5666 | 0.100 |
Why?
|
| Mesenteric Artery, Superior | 1 | 2012 | 77 | 0.100 |
Why?
|
| Postoperative Hemorrhage | 1 | 2013 | 135 | 0.100 |
Why?
|
| Gastric Bypass | 1 | 2013 | 92 | 0.100 |
Why?
|
| Mesenteric Veins | 1 | 2012 | 83 | 0.100 |
Why?
|
| Veins | 1 | 2012 | 165 | 0.100 |
Why?
|
| Early Detection of Cancer | 1 | 2020 | 1339 | 0.100 |
Why?
|
| Endoscopic Ultrasound-Guided Fine Needle Aspiration | 1 | 2013 | 166 | 0.100 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 1994 | 402 | 0.090 |
Why?
|
| Hepatic Artery | 1 | 2012 | 256 | 0.090 |
Why?
|
| Multimodal Imaging | 1 | 2014 | 550 | 0.090 |
Why?
|
| Radiopharmaceuticals | 2 | 2014 | 1341 | 0.090 |
Why?
|
| Drug Delivery Systems | 1 | 2014 | 661 | 0.090 |
Why?
|
| Colonic Neoplasms | 2 | 2013 | 1436 | 0.090 |
Why?
|
| Young Adult | 7 | 2018 | 22178 | 0.090 |
Why?
|
| Predictive Value of Tests | 5 | 2018 | 4961 | 0.090 |
Why?
|
| Portal Vein | 1 | 2012 | 363 | 0.090 |
Why?
|
| Capecitabine | 3 | 2022 | 390 | 0.080 |
Why?
|
| Cyst Fluid | 1 | 2009 | 22 | 0.080 |
Why?
|
| Cystadenoma, Mucinous | 1 | 2009 | 35 | 0.080 |
Why?
|
| Liver Diseases | 2 | 2005 | 602 | 0.080 |
Why?
|
| CA-19-9 Antigen | 1 | 2010 | 155 | 0.080 |
Why?
|
| Albumins | 2 | 2022 | 263 | 0.080 |
Why?
|
| United States | 6 | 2020 | 15817 | 0.080 |
Why?
|
| Kaplan-Meier Estimate | 6 | 2020 | 6253 | 0.080 |
Why?
|
| Surveys and Questionnaires | 2 | 2018 | 5911 | 0.080 |
Why?
|
| Kidney | 3 | 2002 | 2119 | 0.080 |
Why?
|
| Texas | 3 | 2012 | 6433 | 0.080 |
Why?
|
| Celiac Artery | 1 | 2008 | 43 | 0.080 |
Why?
|
| Tissue Banks | 1 | 2008 | 51 | 0.080 |
Why?
|
| Mesenteric Arteries | 1 | 2008 | 64 | 0.070 |
Why?
|
| Models, Anatomic | 1 | 2009 | 146 | 0.070 |
Why?
|
| Mitotane | 1 | 2007 | 41 | 0.070 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2012 | 637 | 0.070 |
Why?
|
| Risk Factors | 4 | 2018 | 17857 | 0.070 |
Why?
|
| Genomics | 1 | 2018 | 2834 | 0.070 |
Why?
|
| Ultrasonography | 4 | 2009 | 1933 | 0.070 |
Why?
|
| Disease Progression | 1 | 2018 | 6851 | 0.070 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2018 | 5775 | 0.070 |
Why?
|
| Portal System | 1 | 2006 | 43 | 0.070 |
Why?
|
| Specimen Handling | 1 | 2008 | 306 | 0.070 |
Why?
|
| Chemoradiotherapy | 3 | 2022 | 2027 | 0.060 |
Why?
|
| Microcomputers | 3 | 2002 | 35 | 0.060 |
Why?
|
| Computer Communication Networks | 3 | 2002 | 43 | 0.060 |
Why?
|
| Treatment Outcome | 10 | 2022 | 33696 | 0.060 |
Why?
|
| Biopsy | 3 | 2018 | 3482 | 0.060 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 2007 | 369 | 0.060 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 1996 | 1737 | 0.060 |
Why?
|
| Adrenal Cortex Neoplasms | 1 | 2007 | 242 | 0.060 |
Why?
|
| Cholecystitis | 1 | 2004 | 59 | 0.060 |
Why?
|
| Information Storage and Retrieval | 2 | 2002 | 121 | 0.060 |
Why?
|
| Fluorodeoxyglucose F18 | 2 | 2007 | 1260 | 0.060 |
Why?
|
| Radiotherapy, High-Energy | 1 | 2005 | 303 | 0.060 |
Why?
|
| Vipoma | 2 | 2013 | 18 | 0.060 |
Why?
|
| Cholangiopancreatography, Endoscopic Retrograde | 2 | 2002 | 173 | 0.060 |
Why?
|
| DNA Adducts | 2 | 2014 | 214 | 0.060 |
Why?
|
| Image Enhancement | 2 | 2018 | 553 | 0.060 |
Why?
|
| Neoplasm Grading | 2 | 2018 | 1822 | 0.050 |
Why?
|
| Patient Care Planning | 1 | 2005 | 302 | 0.050 |
Why?
|
| Emphysema | 1 | 2004 | 88 | 0.050 |
Why?
|
| Paclitaxel | 2 | 2022 | 2100 | 0.050 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2007 | 841 | 0.050 |
Why?
|
| Neoplasm Invasiveness | 3 | 2013 | 4044 | 0.050 |
Why?
|
| Tumor Burden | 2 | 2018 | 2033 | 0.050 |
Why?
|
| Teaching Materials | 1 | 2002 | 23 | 0.050 |
Why?
|
| Cholangiography | 1 | 2001 | 34 | 0.050 |
Why?
|
| Gastrointestinal Stromal Tumors | 1 | 2004 | 318 | 0.050 |
Why?
|
| Feasibility Studies | 2 | 2018 | 2359 | 0.050 |
Why?
|
| Disease-Free Survival | 4 | 2020 | 10258 | 0.050 |
Why?
|
| Gallstones | 1 | 2001 | 64 | 0.050 |
Why?
|
| Multiple Endocrine Neoplasia Type 1 | 2 | 2013 | 143 | 0.050 |
Why?
|
| Cholecystectomy, Laparoscopic | 1 | 2001 | 75 | 0.050 |
Why?
|
| Tertiary Care Centers | 2 | 2013 | 417 | 0.050 |
Why?
|
| Consensus | 2 | 2017 | 1104 | 0.050 |
Why?
|
| Rupture, Spontaneous | 1 | 2000 | 69 | 0.050 |
Why?
|
| Bile Ducts, Intrahepatic | 1 | 2002 | 333 | 0.040 |
Why?
|
| Risk Assessment | 4 | 2020 | 6761 | 0.040 |
Why?
|
| Iohexol | 1 | 2020 | 56 | 0.040 |
Why?
|
| Tomography | 1 | 2020 | 63 | 0.040 |
Why?
|
| Tomography, Emission-Computed | 1 | 2001 | 334 | 0.040 |
Why?
|
| Pelvis | 1 | 2002 | 383 | 0.040 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2005 | 624 | 0.040 |
Why?
|
| Satellite Communications | 1 | 1999 | 5 | 0.040 |
Why?
|
| Radiography, Thoracic | 1 | 2002 | 477 | 0.040 |
Why?
|
| X-Ray Film | 1 | 1999 | 31 | 0.040 |
Why?
|
| Wounds, Nonpenetrating | 1 | 2001 | 224 | 0.040 |
Why?
|
| Fluorouracil | 3 | 2011 | 1989 | 0.040 |
Why?
|
| Induction Chemotherapy | 1 | 2022 | 670 | 0.040 |
Why?
|
| Prospective Studies | 5 | 2014 | 13396 | 0.040 |
Why?
|
| Biopsy, Needle | 1 | 2003 | 1379 | 0.040 |
Why?
|
| DNA, Neoplasm | 2 | 2014 | 1958 | 0.040 |
Why?
|
| Evidence-Based Medicine | 2 | 2017 | 1034 | 0.040 |
Why?
|
| Photography | 1 | 1999 | 125 | 0.040 |
Why?
|
| Time Factors | 4 | 2018 | 12996 | 0.040 |
Why?
|
| Databases, Factual | 2 | 2018 | 2245 | 0.040 |
Why?
|
| Erlotinib Hydrochloride | 1 | 2019 | 398 | 0.040 |
Why?
|
| Mutation | 1 | 2018 | 15901 | 0.040 |
Why?
|
| Bile Duct Neoplasms | 1 | 2002 | 500 | 0.040 |
Why?
|
| Cholangiocarcinoma | 1 | 2002 | 503 | 0.040 |
Why?
|
| Education, Medical | 1 | 2002 | 344 | 0.040 |
Why?
|
| Logistic Models | 2 | 2016 | 3447 | 0.040 |
Why?
|
| Statistics, Nonparametric | 2 | 2013 | 985 | 0.040 |
Why?
|
| Bayes Theorem | 1 | 2022 | 1058 | 0.030 |
Why?
|
| Angiography | 3 | 2005 | 350 | 0.030 |
Why?
|
| Data Collection | 1 | 1999 | 608 | 0.030 |
Why?
|
| Pneumoperitoneum | 1 | 1996 | 18 | 0.030 |
Why?
|
| Drug Administration Schedule | 2 | 2016 | 3528 | 0.030 |
Why?
|
| Survival Analysis | 2 | 2020 | 9290 | 0.030 |
Why?
|
| Sodium Pertechnetate Tc 99m | 1 | 1995 | 4 | 0.030 |
Why?
|
| Multivariate Analysis | 3 | 2012 | 4326 | 0.030 |
Why?
|
| Prevalence | 2 | 2015 | 3399 | 0.030 |
Why?
|
| Secretin | 1 | 2015 | 27 | 0.030 |
Why?
|
| Random Allocation | 1 | 2017 | 741 | 0.030 |
Why?
|
| Neoplasms | 2 | 2016 | 15900 | 0.030 |
Why?
|
| Ascites | 1 | 1996 | 213 | 0.030 |
Why?
|
| Pancreatic Fistula | 1 | 1995 | 102 | 0.030 |
Why?
|
| Tomography Scanners, X-Ray Computed | 1 | 2014 | 89 | 0.030 |
Why?
|
| Equilibrative Nucleoside Transporter 1 | 1 | 2014 | 16 | 0.030 |
Why?
|
| False Positive Reactions | 1 | 1995 | 376 | 0.030 |
Why?
|
| Biological Transport, Active | 1 | 2014 | 129 | 0.030 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2016 | 3993 | 0.030 |
Why?
|
| Models, Theoretical | 1 | 2018 | 798 | 0.030 |
Why?
|
| Cricetinae | 1 | 1995 | 769 | 0.030 |
Why?
|
| Injections, Intravenous | 1 | 2014 | 591 | 0.030 |
Why?
|
| Glucagonoma | 1 | 2013 | 12 | 0.030 |
Why?
|
| Anastomosis, Surgical | 1 | 1995 | 371 | 0.030 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 1995 | 334 | 0.030 |
Why?
|
| Palliative Care | 1 | 2005 | 2173 | 0.030 |
Why?
|
| Biological Transport | 1 | 2014 | 627 | 0.030 |
Why?
|
| Arteriovenous Malformations | 1 | 2013 | 65 | 0.030 |
Why?
|
| Tissue Distribution | 1 | 2014 | 929 | 0.030 |
Why?
|
| Receptors, Somatostatin | 1 | 2013 | 94 | 0.030 |
Why?
|
| Japan | 1 | 2013 | 236 | 0.030 |
Why?
|
| Radiotherapy, Adjuvant | 2 | 2010 | 2269 | 0.030 |
Why?
|
| DNA Mutational Analysis | 1 | 2018 | 2357 | 0.030 |
Why?
|
| Octreotide | 1 | 2013 | 131 | 0.030 |
Why?
|
| Gastrointestinal Agents | 1 | 2013 | 118 | 0.030 |
Why?
|
| Heredity | 1 | 2012 | 26 | 0.030 |
Why?
|
| Radionuclide Imaging | 2 | 2004 | 655 | 0.030 |
Why?
|
| Carcinoma | 1 | 2003 | 2609 | 0.020 |
Why?
|
| Asymptomatic Diseases | 1 | 2012 | 103 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2013 | 749 | 0.020 |
Why?
|
| Survival Rate | 2 | 2018 | 12509 | 0.020 |
Why?
|
| Leukopenia | 1 | 2011 | 152 | 0.020 |
Why?
|
| Biomarkers | 1 | 2022 | 5059 | 0.020 |
Why?
|
| Adolescent | 5 | 2011 | 32693 | 0.020 |
Why?
|
| Terminology as Topic | 1 | 2013 | 417 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2017 | 2846 | 0.020 |
Why?
|
| Esophageal Neoplasms | 1 | 2003 | 3240 | 0.020 |
Why?
|
| Radiotherapy Dosage | 2 | 2010 | 3999 | 0.020 |
Why?
|
| Colorectal Neoplasms | 1 | 2005 | 3707 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2012 | 1312 | 0.020 |
Why?
|
| Carcinoembryonic Antigen | 1 | 2009 | 231 | 0.020 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 1994 | 527 | 0.020 |
Why?
|
| Academic Medical Centers | 1 | 2012 | 681 | 0.020 |
Why?
|
| Hepatectomy | 1 | 1995 | 1012 | 0.020 |
Why?
|
| Neuroblastoma | 1 | 1994 | 705 | 0.020 |
Why?
|
| Endocrine Gland Neoplasms | 1 | 2008 | 43 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2013 | 2310 | 0.020 |
Why?
|
| Treatment Failure | 1 | 2011 | 1428 | 0.020 |
Why?
|
| Taxoids | 1 | 2011 | 1015 | 0.020 |
Why?
|
| Pedigree | 1 | 2012 | 2042 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2018 | 7663 | 0.020 |
Why?
|
| Duodenal Neoplasms | 1 | 2008 | 138 | 0.020 |
Why?
|
| Common Bile Duct Neoplasms | 1 | 2008 | 152 | 0.020 |
Why?
|
| Ampulla of Vater | 1 | 2008 | 160 | 0.020 |
Why?
|
| Cancer Care Facilities | 1 | 2011 | 907 | 0.020 |
Why?
|
| Peptic Ulcer Hemorrhage | 1 | 2006 | 36 | 0.020 |
Why?
|
| Thrombocytopenia | 1 | 2011 | 870 | 0.020 |
Why?
|
| Digestive System | 1 | 2006 | 121 | 0.020 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2016 | 2450 | 0.020 |
Why?
|
| Anemia | 1 | 2011 | 726 | 0.020 |
Why?
|
| Models, Biological | 1 | 2014 | 3194 | 0.020 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2016 | 2161 | 0.020 |
Why?
|
| Autoimmune Diseases | 1 | 2008 | 435 | 0.010 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2005 | 751 | 0.010 |
Why?
|
| Precancerous Conditions | 1 | 2010 | 1059 | 0.010 |
Why?
|
| Tumor Microenvironment | 1 | 2014 | 3029 | 0.010 |
Why?
|
| APACHE | 1 | 2003 | 93 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2018 | 14825 | 0.010 |
Why?
|
| Duodenum | 1 | 2004 | 169 | 0.010 |
Why?
|
| Hospitalization | 1 | 2011 | 2161 | 0.010 |
Why?
|
| Bevacizumab | 1 | 2006 | 958 | 0.010 |
Why?
|
| Multiple Myeloma | 1 | 2013 | 2281 | 0.010 |
Why?
|
| Urography | 1 | 2001 | 57 | 0.010 |
Why?
|
| Amylases | 1 | 2001 | 66 | 0.010 |
Why?
|
| Liver Function Tests | 1 | 2001 | 185 | 0.010 |
Why?
|
| Intraoperative Period | 1 | 2001 | 251 | 0.010 |
Why?
|
| Radiotherapy | 1 | 2008 | 1857 | 0.010 |
Why?
|
| Cisplatin | 1 | 2008 | 2496 | 0.010 |
Why?
|
| Renal Artery Obstruction | 1 | 2000 | 40 | 0.010 |
Why?
|
| Imatinib Mesylate | 1 | 2004 | 1690 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2013 | 9470 | 0.010 |
Why?
|
| Vasculitis | 1 | 2000 | 72 | 0.010 |
Why?
|
| Printing | 1 | 1999 | 7 | 0.010 |
Why?
|
| Data Display | 1 | 1999 | 49 | 0.010 |
Why?
|
| Teleradiology | 1 | 1999 | 13 | 0.010 |
Why?
|
| Computer Graphics | 1 | 1999 | 77 | 0.010 |
Why?
|
| Database Management Systems | 1 | 1999 | 58 | 0.010 |
Why?
|
| Benzamides | 1 | 2004 | 1878 | 0.010 |
Why?
|
| Biomarkers, Tumor | 2 | 2009 | 10699 | 0.010 |
Why?
|
| Comorbidity | 1 | 2005 | 2392 | 0.010 |
Why?
|
| Intensive Care Units | 1 | 2003 | 735 | 0.010 |
Why?
|
| Wounds and Injuries | 1 | 2002 | 441 | 0.010 |
Why?
|
| Acute Disease | 1 | 2003 | 2494 | 0.010 |
Why?
|
| Ischemia | 1 | 2000 | 403 | 0.010 |
Why?
|
| Face | 1 | 1999 | 251 | 0.010 |
Why?
|
| Skull | 1 | 1999 | 251 | 0.010 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2003 | 914 | 0.010 |
Why?
|
| Piperazines | 1 | 2004 | 2145 | 0.010 |
Why?
|
| Melanoma | 1 | 2013 | 5594 | 0.010 |
Why?
|
| Clinical Trials as Topic | 1 | 2006 | 3843 | 0.010 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2006 | 3399 | 0.010 |
Why?
|
| Antibodies, Monoclonal | 1 | 2006 | 4479 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2003 | 4373 | 0.010 |
Why?
|
| Pyrimidines | 1 | 2004 | 3662 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2007 | 17008 | 0.010 |
Why?
|
| Lung Neoplasms | 1 | 2013 | 12020 | 0.010 |
Why?
|
| Animals | 1 | 1995 | 62012 | 0.010 |
Why?
|
| Child | 1 | 2007 | 30500 | 0.000 |
Why?
|
| Brain | 1 | 1999 | 4212 | 0.000 |
Why?
|
| Antineoplastic Agents | 1 | 2004 | 14614 | 0.000 |
Why?
|